Regulation of stathmin phosphorylation in mouse liver progenitor-29 cells during proteasome inhibition

Proteomics

Volumn 9, Issue 19, 2009, Pages 4495-4506

  Santamaría, Enrique ^a   Mora, Maria I ^a   Muñoz, Javier ^a   Sánchez Quiles, Virginia ^a   Fernández Irigoyen, Joaquín ^a   Prieto, Jesús ^a   Corrales, Fernando J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Cell biology; MS; Phosphoprotein; Proteasome inhibition; Stathmin

Indexed keywords

CELL PROTEIN; CHAPERONE; MESSENGER RNA; PHOSPHOPROTEIN; PROTEASOME; SERINE; STATHMIN;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CELL CYCLE REGULATION; EMBRYO; INHIBITION KINETICS; LIQUID CHROMATOGRAPHY; LIVER; MASS SPECTROMETRY; MOUSE; N MYC DOWNSTREAM REGULATED GENE 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RNA PROCESSING; STEM CELL; STRESS;

ANIMALS; CELL CYCLE PROTEINS; CELL LINE; CYSTEINE PROTEINASE INHIBITORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUPEPTINS; LIVER; MICE; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; STATHMIN; STEM CELLS;

EID: 70350238656     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200900110     Document Type: Article

References (73)

1. Lee, D. H., Goldberg, A. L., Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 1998, 8, 397-403.
2. Goldberg, A. L., Protein degradation and protection against misfolded or damaged proteins. Nature 2003, 426, 895-899.
3. Kisselev, A. F., Goldberg, A. L., Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 2001, 8, 739-758. (Pubitemid 32752454)
4. Perez, M. J., Cederbaum, A. I., Proteasome inhibition potentiates CYP2E1-mediated toxicity in HepG2 cells. Hepatology 2003, 37, 1395-1404.
5. Meng, L., Mohan, R., Kwok, B. H., Elofsson, M. et al., Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. USA 1999, 96, 10403-10408. (Pubitemid 29422570)
6. Drexler, H. C., Activation of the cell death program by inhibition of proteasome function. Proc. Natl. Acad. Sci. USA 1997, 94, 855-860. (Pubitemid 27074411)
7. Drexler, H. C., Risau, W., Konerding, M. A., Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEb J. 2000, 14, 65-77. (Pubitemid 30051524)
8. Oikawa, T., Sasaki, T., Nakamura, M., Shimamura, M. et al., The proteasome is involved in angiogenesis. Biochem. Biophys. Res. Commun. 1998, 246, 243-248.
9. Richardson, P. G., Mitsiades, C., Hideshima, T., Anderson, K. C., Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu. Rev. Med. 2006, 57, 33-47. (Pubitemid 43261977)
10. Lenz, H. J., Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev. 2003, 29, 41-48. (Pubitemid 36626291)
11. Ganten, T. M., Koschny, R., Haas, T. L., Sykora, J. et al., Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to trail. Hepatology 2005, 42, 588-597. (Pubitemid 41233651)
12. Anan, A., Baskin-Bey, E. S., Bronk, S. F., Werneburg, N. W. et al., Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology 2006, 43, 335-344. (Pubitemid 43304001)
13. Anan, A., Baskin-Bey, E. S., Isomoto, H., Mott, J. L. et al., Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291, 709-716. (Pubitemid 44511688)
14. Dy, G. K., Thomas, J. P., Wilding, G., Bruzek, L. et al., A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin. Cancer Res. 2005, 11, 3410-3416. (Pubitemid 40627894)
15. Zavrski, I., Jakob, C., Schmid, P., Krebbel, H. et al., Proteasome: an emerging target for cancer therapy. Anticancer Drugs 2005, 16, 475-481. (Pubitemid 40685731)
16. Landowski, T. H., Megli, C. J., Nullmeyer, K. D., Lynch, R. M., Dorr, R. T., Mitochondrial-mediated disregulation of Ca21is a critical determinant of velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res. 2005, 65, 3828-3836.
17. Mulligan, G., Mitsiades, C., Bryant, B., Zhan, F. et al., Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007, 109, 3177-3188. (Pubitemid 46572502)
18. Concannon, C. G., Koehler, B. F., Reimertz, C., Murphy, B. M. et al., Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway. Oncogene 2007, 26, 1681-1692. (Pubitemid 46426201)
19. Yew, E. H., Cheung, N. S., Choy, M. S., Qi, R. Z. et al., Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and proapoptotic transcriptional responses: a microarray analysis. J. Neurochem. 2005, 94, 943-956.
20. Tang, Z. Y., Wu, Y. L., Gao, S. L., Shen, H. W., Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells. J. Surg. Res. 2008, 145, 111-123.
21. Fribley, A., Zeng, Q., Wang, C. Y., Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol. Cell. Biol. 2004, 24, 9695-9704. (Pubitemid 39458799)
22. Zimmermann, J., Erdmann, D., Lalande, I., Grossenbacher, R. et al., Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1. Oncogene 2000, 19, 2913-2920. (Pubitemid 30389081)
23. Poulaki, V., Mitsiades, C. S., Kotoula, V., Negri, J. et al., The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. Invest. Ophthalmol. Vis. Sci. 2007, 48, 4706-4719. (Pubitemid 351260989)
24. Yang, W., Monroe, J., Zhang, Y., George, D. et al., Proteasome inhibition induces both pro- and anti-cell death pathways in prostate cancer cells. Cancer Lett. 2006, 243, 217-227. (Pubitemid 44485853)
25. Doll, D., Sarikas, A., Krajcik, R., Zolk, O., Proteomic expression analysis of cardiomyocytes subjected to proteasome inhibition. Biochem. Biophys. Res. Commun. 2007, 353, 436-442. (Pubitemid 46014582)
26. Jin, B. F., He, K., Wang, H. X., Wang, J. et al., Proteomic analysis of ubiquitin-proteasome effects: insight into the function of eukaryotic initiation factor 5A. Oncogene 2003, 22, 4819-4830. (Pubitemid 36981270)
27. Zhang, L., Chang, M., Li, H., Hou, S. et al., Proteomic changes of PC12 cells treated with proteasomal inhibitor PSI. Brain Res. 2007, 1153, 196-203. (Pubitemid 46802523)
28. Vasilescu, J., Smith, J. C., Ethier, M., Figeys, D., Proteomic analysis of ubiquitinated proteins from human MCF-7 breast cancer cells by immunoaffinity purification and mass spectrometry. J. Proteome Res. 2005, 4, 2192-2200. (Pubitemid 41814287)
29. Mitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V. et al., The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101, 2377-2380. (Pubitemid 36302084)
30. Choi, M. R., Najafi, F., Safa, A. R., Drexler, H. C., Analysis of changes in the proteome of HL-60 promyeloid leukemia cells induced by the proteasome inhibitor PSI. Biochem. Pharmacol. 2008, 75, 2276-2278.
31. Rajkumar, S. V., Richardson, P. G., Hideshima, T., Anderson, K. C., Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 2005, 23, 630-639. (Pubitemid 46224241)
32. Medico, E., Mongiovi, A. M., Huff, J., Jelinek, M. A. et al., The tyrosine kinase receptors Ron and Sea control scattering and morphogenesis of liver progenitor cells in vitro. Mol. Biol. Cell. 1996, 7, 495-504. (Pubitemid 26112558)
33. Muller, M., Morotti, A., Ponzetto, C., Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol. Cell. Biol. 2002, 22, 1060-1072. (Pubitemid 34094843)
34. Santamaria, E., Avila, M. A., Latasa, M. U., Rubio, A. et al., Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc. Natl. Acad. Sci. USA 2003, 100, 3065-3070. (Pubitemid 36356540)
35. Munoz, J., Fernandez-Irigoyen, J., Santamaria, E., Parbel, A. et al., Mass spectrometric characterization of mitochondrial complex I ndufa10 variants. Proteomics 2008, 8, 1898-1908. (Pubitemid 351678291)
36. Piquemal, D., Joulia, D., Balaguer, P., Basset, A. et al., Differential expression of the RTP/Drg1/Ndr1 gene product in proliferating and growth arrested cells. Biochim. Biophys. Acta 1999, 1450, 364-373. (Pubitemid 29295486)
37. Tu, L. C., Yan, X., Hood, L., Lin, B., Proteomics analysis of the interactome of N-myc downstream regulated gene 1 and its interactions with the androgen response program in prostate cancer cells. Mol. Cell. Proteomics 2007, 6, 575-588. (Pubitemid 46630091)
38. Ahn, J., Murphy, M., Kratowicz, S., Wang, A. et al., Downregulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 1999, 18, 5954-5958. (Pubitemid 29520452)
39. Sobel, A., Stathmin: A relay phosphoprotein for multiple signal transduction?. Trends Biochem. Sci. 1991, 16, 301-305.
40. Puente, L. G., Borris, D. J., Carriere, J. F., Kelly, J. F., Megeney, L. A., Identification of candidate regulators of embryonic stem cell differentiation by comparative phosphoprotein affinity profiling. Mol. Cell. Proteomics 2006, 5, 57-67.
41. Hermann, R., Hensel, F., Muller, E. C., Keppler, M. et al., Deactivation of regulatory proteins hnRNP A1 and A2 during SC-1 induced apoptosis. Hum. Antibodies 2001, 10, 83-90. (Pubitemid 32980263)
42. Murray, J. T., Campbell, D. G., Morrice, N., Auld, G. C. et al., Exploitation of kestrel to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem. J. 2004, 384, 477-488. (Pubitemid 40018961)
43. Stein, S., Thomas, E. K., Herzog, B., Westfall, M. D. et al., NDRG1 is necessary for p53-dependent apoptosis. J. Biol. Chem. 2004, 279, 48930-48940.
44. Almond, J. B., Cohen, G. M., The proteasome: a novel target for cancer chemotherapy. Leukemia 2002, 16, 433-443. (Pubitemid 34449723)
45. Liu, Z., Lu, H., Shi, H., Du, Y. et al., PUMA overexpression induces reactive oxygen species generation and proteasome- mediated stathmin degradation in colorectal cancer cells. Cancer Res. 2005, 65, 1647-1654. (Pubitemid 40478588)
46. Johnsen, J. I., Aurelio, O. N., Kwaja, Z., Jorgensen, G. E. et al., p53-Mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. Int. J. Cancer 2000, 88, 685-691. (Pubitemid 30819131)
47. Jiang, L., Chen, Y., Chan, C. Y., Wang, X. et al., Downregulation of stathmin is required for TGF-beta inducible early gene 1 induced growth inhibition of pancreatic cancer cells. Cancer Lett. 2008, 274, 101-108.
48. Vancompernolle, K., Boonefaes, T., Mann, M., Fiers, W., Grooten, J., Tumor necrosis factor-induced microtubule stabilization mediated by hyperphosphorylated oncoprotein 18 promotes cell death. J. Biol. Chem. 2000, 275, 33876-33882. (Pubitemid 30808613)
49. Nakamura, K., Zhang, X., Kuramitsu, Y., Fujimoto, M. et al., Analysis on heat stress-induced hyperphosphorylation of stathmin at serine 37 in Jurkat cells by means of twodimensional gel electrophoresis and tandem mass spectrometry. J. Chromatogr. A 2006, 1106, 181-189. (Pubitemid 43145850)
50. Beretta, L., Dubois, M. F., Sobel, A., Bensaude, O., Stathmin is a major substrate for mitogen-activated protein kinase during heat shock and chemical stress in HeLa cells. Eur. J. Biochem. 1995, 227, 388-395.
51. Melhem, R., Hailat, N., Kuick, R., Hanash, S. M., Quantitative analysis of Op18 phosphorylation in childhood acute leukemia. Leukemia 1997, 11, 1690-1695. (Pubitemid 27458608)
52. Wang, Y. K., Liao, P. C., Allison, J., Gage, D. A. et al., Phorbol 12-myristate 13-acetate-induced phosphorylation of Op18 in Jurkat T cells. Identification of phosphorylation sites by matrix-assisted laser desorption ionization mass spectrometry. J. Biol. Chem. 1993, 268, 14269-14277. (Pubitemid 23195552)
53. Beretta, L., Dobransky, T., Sobel, A., Multiple phosphorylation of stathmin. Identification of four sites phosphorylated in intact cells and in vitro by cyclic AMP-dependent protein kinase and p34cdc2. J. Biol. Chem. 1993, 268, 20076-20084. (Pubitemid 23278904)
54. Beretta, L., Houdouin, F., Sobel, A., Identification of two distinct isoforms of stathmin and characterization of their respective phosphorylated forms. J. Biol. Chem. 1989, 264, 9932-9938. (Pubitemid 19159260)
55. Doye, V., Le Gouvello, S., Dobransky, T., Chneiweiss, H. et al., Expression of transfected stathmin cDNA reveals novel phosphorylated forms associated with developmental and functional cell regulation. Biochem. J. 1992, 287, 549-554.
56. Brattsand, G., Marklund, U., Nylander, K., Roos, G., Gullberg, M., Cell-cycle-regulated phosphorylation of oncoprotein 18 on Ser16, Ser25 and Ser38. Eur. J. Biochem. 1994, 220, 359-368. (Pubitemid 24092800)
57. le Gouvello, S., Manceau, V., Sobel, A., Serine 16 of stathmin as a cytosolic target for Ca21/calmodulin-dependent kinase II after CD2 triggering of human T lymphocytes. J. Immunol. 1998, 161, 1113-1122. (Pubitemid 28380535)
58. Monnet, C., Gavard, J., Mege, R. M., Sobel, A., Clustering of cellular prion protein induces ERK1/2 and stathmin phosphorylation in GT1-7 neuronal cells. FEBS Lett. 2004, 576, 114-118. (Pubitemid 39330467)
59. Fahrmann, M., Honisch, S., Kaufhold, M. A., Leitges, M., Beil, W., Stringent time-dependent transregulation of calcium calmodulin kinase II (CaMKII) is implicated in antiapoptotic control. Biochim. Biophys. Acta 2008, 1783, 214-223.
60. Krakstad, C., Herfindal, L., Gjertsen, B. T., Boe, R. et al., CaM-kinaseII-dependent commitment to microcystininduced apoptosis is coupled to cell budding, but not to shrinkage or chromatin hypercondensation. Cell Death Differ. 2006, 13, 1191-1202. (Pubitemid 43905599)
61. Chen, J. J., Chou, C. W., Chang, Y. F., Chen, C. C., Proteasome inhibitors enhance trail-induced apoptosis through the intronic regulation of dr5: involvement of NF-kappaB and reactive oxygen species-mediated p53 activation. J. Immunol. 2008, 180, 8030-8039.
62. Means, A. R., Regulatory cascades involving calmodulindependent protein kinases. Mol. Endocrinol. 2000, 14, 4-13.
63. Nawrocki, S. T., Sweeney-Gotsch, B., Takamori, R., McConkey, D. J., The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol. Cancer Ther. 2004, 3, 59-70. (Pubitemid 39193679)
64. Yin, D., Zhou, H., Kumagai, T., Liu, G. et al., Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005, 24, 344-354. (Pubitemid 40188583)
65. Gu, Y., Rosenblatt, J., Morgan, D. O., Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J. 1992, 11, 3995-4005.
66. Yu, C., Rahmani, M., Dent, P., Grant, S., The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp. Cell Res. 2004, 295, 555-566. (Pubitemid 38490507)
67. Melander Gradin, H., Marklund, U., Larsson, N., Chatila, T. A., Gullberg, M., Regulation of microtubule dynamics by Ca21/calmodulin-dependent kinase IV/Gr-dependent phosphorylation of oncoprotein 18. Mol. Cell. Biol. 1997, 17, 3459-3467. (Pubitemid 27215061)
68. Larsson, N., Marklund, U., Gradin, H. M., Brattsand, G., Gullberg, M., Control of microtubule dynamics by oncoprotein 18: Dissection of the regulatory role of multisite phosphorylation during mitosis. Mol. Cell. Biol. 1997, 17, 5530-5539. (Pubitemid 27357649)
69. Larsson, N., Melander, H., Marklund, U., Osterman, O., Gullberg, M., G2/M transition requires multisite phosphorylation of oncoprotein 18 by two distinct protein kinase systems. J. Biol. Chem. 1995, 270, 14175-14183.
70. Curmi, P. A., Gavet, O., Charbaut, E., Ozon, S. et al., Stathmin and its phosphoprotein family: general properties, biochemical and functional interaction with tubulin. Cell Struct. Funct. 1999, 24, 345-357.
71. Amayed, P., Carlier, M. F., Pantaloni, D., Stathmin slows down guanosine diphosphate dissociation from tubulin in a phosphorylation-controlled fashion. Biochemistry 2000, 39, 12295-12302. (Pubitemid 30761167)
72. Molina, H., Horn, D. M., Tang, N., Mathivanan, S., Pandey, A., Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc. Natl. Acad. Sci. USA 2007, 104, 2199-2204. (Pubitemid 46391375)
73. Munton, R. P., Tweedie-Cullen, R., Livingstone-Zatchej, M., Weinandy, F. et al., Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations. Mol. Cell. Proteomics 2007, 6, 283-293. (Pubitemid 46359516)